Oakland, CA, United States of America

Ephraim Heller

USPTO Granted Patents = 126 

 

 

Average Co-Inventor Count = 7.9

ph-index = 33

Forward Citations = 21,441(Granted Patents)

Forward Citations (Not Self Cited) = 20,464(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Alameda, CA (US) (1998 - 2012)
  • Piedmont, CA (2013)
  • Oakland, CA (US) (1997 - 2015)
  • Piedmont, CA (US) (2011 - 2018)
  • Wilson, WY (US) (2015 - 2022)

Company Filing History:


Years Active: 1997-2022

Loading Chart...
Loading Chart...
Loading Chart...
126 patents (USPTO):Explore Patents

Title: Nanoparticle-Based Drug Delivery System: Revolutionizing Therapeutic Efficacy

Introduction:

In the world of medical innovation, Ephraim Heller, a prominent inventor based in Oakland, CA (US), has made significant contributions through the development of a groundbreaking nanoparticle-based drug delivery system. This patent presents a novel approach that enhances the targeted delivery and efficacy of therapeutic agents, revolutionizing the field of drug delivery.

Latest Patents:

Ephraim Heller has a remarkable track record, with 126 patents to his name. Among his latest patents are "Devices for the Administration of Pharmaceutical Suspensions." This invention introduces a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth, and associated methods of continuous administration. By ensuring sustained, controlled drug release, this patent addresses the challenge of optimizing therapeutic effectiveness while minimizing side effects.

Career Highlights:

Ephraim Heller's career is adorned with numerous noteworthy achievements. Notably, he has contributed his expertise to renowned companies such as Abbott Diabetes Care Inc. and Therasense, Inc. (now part of Abbott). Through his work at these companies, Heller has paved the way for groundbreaking advancements in medical technology, particularly in diabetes management and drug delivery systems.

Collaborations:

Throughout his career, Ephraim Heller has collaborated with distinguished individuals, including Adam Heller and Fredric C Colman. Adam Heller, a renowned researcher and inventor, has made significant contributions to the field of biotechnology, particularly in glucose monitoring and insulin delivery. Fredric C Colman, another esteemed collaborator, has vast experience in medical device development and has played an instrumental role in the creation of innovative solutions for healthcare challenges.

Conclusion:

Ephraim Heller's nanoparticle-based drug delivery system patent opens new horizons in the field of therapeutic efficacy. By utilizing nanoparticles, this system enhances targeted drug delivery, reducing potential side effects while maximizing treatment effectiveness. Heller's impressive career, marked by successful collaborations and a multitude of patents, continues to elevate the medical technology industry. Through his groundbreaking inventions, Ephraim Heller exemplifies the spirit of innovation and contributes to the advancement of patient care worldwide.

For more insights on inventors, patents, and innovations, visit our website: idiyas.com.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…